The patient population chosen for the trial has stage II or III breast cancer with a tumor size of at least 2.5 cm and with stratification by nodal status, hormone receptor status, HER2 status, and the 70-gene MammaPrint (Agendia) assay9,10,36,41. This evidence concerns the gene ERBB2 and neoplasm.